<DOC>
	<DOCNO>NCT01000649</DOCNO>
	<brief_summary>The purpose trial examine safety tolerability , pharmacokinetics FE202158 ass whether stabilize blood pressure reduce vascular ( blood vessel ) leakage . FE 202158 previously test healthy volunteer .</brief_summary>
	<brief_title>Effects V1a Agonist FE 202158 Patients With Septic Shock</brief_title>
	<detailed_description />
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<criteria>Signed informed consent form patient legal representative accord local regulation Man woman 18 year age old Proven suspect infection Low blood pressure Signs decrease circulation tissue Willing use adequate barrier method hormonal method contraception , abstinent , day inform consent one week end infusion study medication . Present history ( within last 5 year ) acute coronary syndrome ( myocardial infarction unstable angina ) . Patients asymptomatic 6 month coronary revascularisation eligible . Hypovolaemia suspect clinical ground , e.g . cold extremity delay capillary filling , low cardiac filling pressure , mark systolic pulse pressure variation positive leg raise test . Known suspected cardiac failure Pregnancy breastfeed Any cause hypotension early septic shock Use vasopressin terlipressin blood pressure support current hospital admission Proven suspect acute mesenteric ischemia , judge investigator Known episode septic shock within 1 month prior randomisation Underlying chronic heart disease Traumatic brain injury Present hospitalisation burn injury Symptomatic peripheral vascular disease include Raynaud 's syndrome Previously randomise trial Intake investigational drug within last 3 month ( longer judge Investigator possibly influence outcome current study ) Known participation another clinical trial Considered investigator unsuitable participate trial reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>V1a agonist</keyword>
</DOC>